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The effects and impact of second-hand cannabis smoke exposure on
nurses working in the community
Abstract
This article explores the work, health and safety risks that may be associated with the exposure of nurses to
second-hand cannabis smoke while working in the community. Emerging evidence suggests the benefits of
cannabis in the treatment of several chronic and terminal illnesses. This has led to some countries, like
Australia, decriminalising or legalising the use of cannabis for medicinal purposes. Smoked cannabis is one of
several routes of administration. However, cannabis smoke may have an impact on those in close proximity to
the consuming patient. As a result, community healthcare workers, including nurses, may passively inhale
cannabis substances while visiting patients in their home. This poses a work health and safety risk to the
community nurses and other healthcare workers. This review intends to raise awareness of this fact and reveals
that more research and education is needed to strengthen policies and procedures around the nursing
practices in the care of patients who choose to use smoked medicinal cannabis for symptom management. The
successful use of cannabis in the treatment of a range of chronic or terminal medical conditions, such as
chemotherapy-induced nausea and vomiting, palliative care patients or childhood epilepsy, is currently widely
discussed and reported around in the media and specialised literature (Suraev et al. 2017; Wong & Wilens
2017; Hausman-Kedem & Kramer 2017; Abrams 2018). The use and cultivation of cannabis for any purposes
in Australia, including medical research for acute and chronic disease management, has been prohibited since
the early twentieth century (Rodman 2015).
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ABSTRACT:
This article explores the work, health and 
safety risks that may be associated with 
the exposure of nurses to second-hand 
cannabis smoke while working in the 
community. Emerging evidence suggests 
the benefits of cannabis in the treatment 
of several chronic and terminal illnesses. 
This has led to some countries, like 
Australia, decriminalising or legalising the 
use of cannabis for medicinal purposes. 
Smoked cannabis is one of several routes 
of administration. However, cannabis 
smoke may have an impact on those in 
close proximity to the consuming patient. 
As a result, community healthcare 
workers, including nurses, may passively 
inhale cannabis substances while visiting 
patients in their home. This poses a work 
health and safety risk to the community 
nurses and other healthcare workers. 
This review intends to raise awareness of 
this fact and reveals that more research 
and education is needed to strengthen 
policies and procedures around the 
nursing practices in the care of patients 
who choose to use smoked medicinal 
cannabis for symptom management. 
The successful use of cannabis in the 
treatment of a range of chronic or 
terminal medical conditions, such as 
chemotherapy-induced nausea and 
vomiting, palliative care patients or 
childhood epilepsy, is currently widely 
discussed and reported around in 
the media and specialised literature 
(Suraev et al. 2017; Wong & Wilens 
2017; Hausman-Kedem & Kramer 2017; 
Abrams 2018). The use and cultivation of 
cannabis for any purposes in Australia, 
including medical research for acute and 
chronic disease management, has been 
prohibited since the early twentieth 
century (Rodman 2015). 
OVERVIEW OF THE ISSUE:
Possession of cannabis is illegal in most 
countries, and even the death penalty 
may apply for the sale and possession of 
cannabis in some countries (Edwards et al. 
2011). In general, the negative portrayal of 
cannabis is not only associated with drug 
addiction and health behavioural issues 
(Agrawal et al. 2016; Agrawal & Lynskey 2006; 
Agrawal et al. 2017), but also associated with 
criminal offences by the media and general 
public (Pedersen & Skardhamar 2010; Morris 
et al. 2014). 
However, emerging evidence suggesting the 
usefulness of cannabis as medical therapy, 
and the increase in patients supported 
who are suffering these conditions in the 
community has led several countries, 
including Australia, towards legalising or 
decriminalising the use of cannabis for 
medicinal purposes. 
The effects and impact of 
second-hand cannabis smoke 
exposure on nurses working in 
the community
CLINICAL UPDATE
RISKS TO HEALTH IN 
THE TARGET GROUP 
(COMMUNITY NURSES):
While smoking cannabis is not a route of 
administration supported by the Australian 
Therapeutic Goods Administration, patients 
may choose to inhale cannabis smoke as a 
treatment modality at home, unaware that 
this may pose a work health and safety risk 
to the nurses and other healthcare workers 
who visit patients in the community. 
PROJECT OUTLINE:
This article represents a synthesis of 
relevant literature for nursing practice 
exploring the effects and possible impact of 
second-hand medicinal cannabis smoking 
on nurses working in the community. The 
authors examine key findings identified 
and provide analysis of their relevance to 
nursing and healthcare workers working in 
the community. 
A literature review was undertaken to 
find publications related to second-hand 
cannabis smoke. The databases searched 
were Web of Science, Scopus and CINAHL. 
The search terms used were cannab* OR 
marijuana AND (“secondhand” OR “second-
hand” OR “second hand”) AND smok*. A 
total of 88 papers were identified across 
the search: CINAHL (42), Web of Science (9) 
and SCOPUS (36). The search highlighted 
a limited evidence based on the impact of 
second-hand cannabis smoke on human 
subjects. There was no primary research 
on health professionals’ exposure to 
second-hand cannabis smoke, using either 
qualitative or quantitative methods.
RESULTS
THE EFFECTS OF 
CANNABIS SMOKE
With the increased use of cannabis, there 
has been a growing concern about its 
possible adverse effects. While there are a 
variety of modes of delivery, the fastest route 
of absorption of the active components of 
cannabis, tetrahydrocannabinol (THC) and 
cannabidiol (CBD), is via the respiratory 
system (Grotenhermen 2003). Thus, smoked 
cannabis is the most common form of 
consumption of cannabis for recreational 
use (Newmeyer et al. 2017). 
Although smoking cannabis is the only 
route of administration not recommended 
by the Australian Therapeutics Goods 
Administration due to the harmful effects of 
smoke, its fast absorption (Grotenhermen 
2003) could facilitate the titration when 
used for medicinal purposes, and may be 
the chosen route by the patient looking 
for fast symptom relief. Cannabis can be 
smoked alone, but it is most regularly mixed 
with tobacco (Meier & Hatsukami 2016). 
Smoke from both cannabis and tobacco 
contains a mixture of compounds, 
including carcinogenic molecules and tars 
known to be the culprit of damaging effects 
of smoking (Hoffmann et al. 2001), although 
to differing degrees depending on which 
substance is smoked (Melamede 2005). 
A logical inference is that the effects  
of cannabis smoke could also affect 
second-hand smokers (Holitzki et al. 2017), 
including nurses working in the community 
who may unconsciously and/or passively  
be exposed at times to the smoke of 
cannabis. 
THC is the compound in cannabis that 
causes hallucinogenic results (Johannigman 
& Eschiti 2013). The THC from a typical 
cannabis cigarette that is absorbed by the 
mainstream smoker is found to be in the 
range of 20-37%. 
Pyrolysis further destroys approximately 
30% of the THC and the remaining 40-50% 
is released as side-stream smoke into the 
environment. In addition, there are further 
contaminants from the exhalation of the 
mainstream smoke. Therefore, regardless 
of the many factors that affect absorption 
of THC, there is a likelihood of passive 
inhalation of THC in non-smokers in an 
environment where cannabis is being 
smoked (Berthet et al. 2016).
HEALTH RISKS OF SECOND-
HAND CANNABIS SMOKE
The effect of second-hand cannabis 
smoke (SHCS) must be considered in the 
discussion of using cannabis products as 
a treatment modality in the community. 
SHCS is defined as a combination of the 
side-stream smoke that is emitted from the 
cannabis cigarette and the exhaled smoke 
from the mainstream smoker (Office on 
Smoking and Health 2006). The effects of 
second-hand tobacco smoking have been 
extensively investigated. It is known that 
non-smokers exposed to second-hand 
smoke from tobacco have a 30% increased 
risk of cerebral vascular attack (CVA) (Malek 
et al. 2015), and that it can affect cognitive 
function (Heffernan & O’Neill 2013) and 
even future dependence (Wilson-Frederick 
et al. 2011). 
However, the effects of SHCS are less well 
known due to cannabis being illegal until 
recently in most countries, which made 
research difficult to conduct.
SHCS from combustible cannabis has 
similar health risks to second-hand tobacco 
smoke due to the combustive organic 
material, which creates carcinogenic 
and mutagenic effects (Cone et al. 2015a). 
Cannabis contains many of the same toxins 
in tobacco, which are responsible for 
cardiovascular damage. In fact, many toxins 
such as ammonia, nitric oxide and hydrogen 
cyanide, are found in levels between three 
to 20 times higher in cannabis than in 
tobacco (American Chemical Society 2007). 
Studies in rodents (Wang et al. 2016) have 
demonstrated that exposure to cannabis 
smoke for as little as one minute impairs 
cardiovascular function for the following 
90 minutes. Long-term effects of repeated 
endothelial dysfunction can lead to 
cardiovascular disease including thrombus 
formation, CVA and myocardial infarction 
(Rajendran et al. 2013). 
The study by Wang et al. (2016) also noted 
a longer deleterious cardiovascular effect 
after second-hand exposure to smoke 
from cannabis versus tobacco. This is a 
very significant finding, because the nurse 
visiting a patient who may be smoking 
cannabis for medicinal purposes would 
most likely be exposed for more than 
60 seconds. In attempts to decrease the 
THC levels, and thus the hallucinogenic 
effects, of medical cannabis by changing 
environmental factors, the study found 
that the endothelial dysfunction was 
independent of the level of THC of the 
cannabis (Wang et al. 2016). Thus, even if 
medicinal cannabis has reduced levels of 
THC, SHCS exposure may still affect the 
nurse’s endothelial function.
In humans, subjective drug effects of 
cannabis smoke inhaled passively have 
been found to be dose-dependent (Cone et 
al. 2015b). Therefore the impact on health 
practitioners of SHCS used by patients 
should not be underestimated, particularly 
since few health providers, including 
nurses, felt completely knowledgeable 
about marijuana (cannabis) health risks 
(Brooks et al. 2017), and may not avoid 
exposure during their home visit to patients 
utilising smoked medical cannabis.
A question that often arises is whether SHCS 
will cause blood levels to be high enough 
to test positive in the nurse who is exposed 
and if so, what effect may that have on the 
nurse’s cognition? Hours after secondary 
exposure to cannabis smoke, THC can be 
detected in screening tests of urine (Cone 
et al. 2015a) and oral fluids (Cone et al. 
2015b), although only after exposure to high 
smoke concentrations. However, adequate 
room ventilation may reduce the level of 
secondary exposure to cannabis compounds 
(Herrmann et al. 2015; Cone et al. 2015a). 
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This is an important issue that health 
practitioners should pay attention to when 
carrying out their duty at the patients’ 
home. A study conducted by Cone et 
al. (2015a) demonstrated that short-
term exposure to cannabis smoke in an 
unventilated space produced absorption of 
sufficient amounts of THC for non-smokers 
to test positive for THC up to three hours 
following exposure. In their systematic 
review of passive exposure to cannabis 
smoke, Berthet et al. (2016) advised ‘experts 
should clearly inform persons who have 
to demonstrate prolonged abstinence 
from cannabis to avoid heavily smoky 
and unventilated areas’ (p. 110). Similarly, 
Holitzki et al. (2017) also recommend that 
clinicians advise cannabis users to smoke 
only in open outdoor spaces due to the 
effects of SHCS. This research would seem 
to indicate the need for nurses to avoid 
exposure to cannabis smoke in unventilated 
spaces, not just for potential negative 
implications on their health, but also 
potential legal implications. It also poses 
the question as to how this may impact 
a nurse’s performance as well as driving 
ability after visiting a patient who has been 
smoking medical cannabis during the visit.
POTENTIAL WORK HEALTH 
AND SAFETY RISKS TO THE 
COMMUNITY NURSES
Nurses working in the community are 
often required to commute between visits. 
All states and territories in Australia have 
laws making it an offence to operate a 
vehicle while under the influence of drugs. 
These laws allow the police to initiate drug 
testing if they suspect a driver of a vehicle is 
under the influence of an illicit substance. 
In addition to this, over the last decade 
random roadside drug testing of drivers has 
become a common feature on Australian 
roads. Road-side drug testing determines 
the presence or absence of cannabis, ecstasy 
or amphetamines in oral fluid samples 
(Wilson 2012). The approach to the results 
differs by state. 
For example, Queensland Police (2016) 
note in their guidelines on random 
roadside drug testing ‘any trace of the 
nominated drugs in your system and 
you can be penalised’. While there is no 
universal threshold to differentiate active 
smokers from SHCS (Holitzki et al 2017), the 
government of South Australia (2017) has 
reported the level of THC present in saliva as 
a result of passive smoking is considerably 
lower than the lowest level of THC able to be 
detected by the saliva testing devices. After 
a positive result in a drug test, penalties 
include fines, licence disqualification and 
imprisonment, depending on the nature 
of the offence. In addition, the healthcare 
registration board may require them to go 
through the disciplinary hearing process 
because it constitutes a breach of the 
professional conduct, as they are under the 
influence of illicit substances while on duty. 
Importantly for nurses, their registration 
may be suspended until the hearing process 
is completed.
The advice of Berthet et al. (2016) on 
avoiding exposure to cannabis smoke 
in unventilated areas has particular 
implications for those nurses who have 
conditions placed on their registration 
as a consequence of substance related 
impairment. Australian Health Practitioner 
Regulation Agency (AHPRA) and 
the Nursing and Midwifery Board of 
Australia (NMBA) have drug testing for 
all practitioners with substance related 
impairment (AHPRA 2015). These nurses 
have routine hair and urine testing of a 
wide range of drugs, not just based on 
the nurse’s drug taking history (AHPRA 
2015). Moosmann et al. (2014) have noted 
that ‘considering the severe consequences 
people concerned may experience, 
contamination issues in hair analysis still do 
not seem to be investigated to an extent that 
would be desirable’ (p.125). 
Exposure to medicinal cannabis 
through SHCS could lead to the external 
contamination of hair, yielding false-
positive results (Baciu et al. 2015). 
Furthermore, SHCS can lead to enough 
cannabinoid presence in oral fluids, blood 
and urine so as to give a positive result in 
a drug test (Holitzki et al. 2017). Therefore, 
given the potential impact that SHCS can 
have on a nurse, appropriate consideration 
should be included in the discussion of 
the use of medical cannabis, including 
education of the health practitioners on 
these aspects.
It should be noted that each state and 
territory has its own regulatory frameworks 
for the access to medicinal cannabis 
(Commonwealth of Australia 2017). 
According to the Guidance for the 
use of medicinal cannabis in Australia 
(Commonwealth of Australia 2017), 
nabiximols (an oro-mucosal spray) is 
the only registered cannabis product in 
Australia. 
All other cannabis products must be 
accessed through clinical trials and limited 
Special Access Schemes, regulated and 
monitored by the Therapeutic Goods 
Administration (TGA). 
In principle, the routes of medicinal 
cannabis administration may include oral 
administration, oro-mucosal sprays, topical 
and vaporising. 
However vaporised cannabis may pose 
a risk of SHCS to the nurses during the 
patient visit, especially as no vaporisers are 
currently registered as medical devices in 
Australia (Commonwealth of Australia 2017). 
The impact of cannabis administered by 
routes other than smoking on nurses, and 
the use of other cannabis products such as 
oils or sprays requires independent analysis. 
A final work health and safety factor to 
consider is the effect of SHCS on the foetus 
in the case of a pregnant nurse. There 
are studies that show prenatal exposure 
to cannabis is linked to higher rates of 
stillbirth, shorter length at birth and 
smaller head circumference. Therefore, 
there is suspicion that SHCS may have 
similar effects on the foetus. 
A question that often 
arises is whether SHCS 
will cause blood levels 
to be high enough to test 
positive in the nurse who 
is exposed and if so,  
what effect may that have  
on the nurse’s cognition? 
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In fact, the American College of Obstetrician 
and Gynecologists (ACOG) have stated 
that there is data of the negative impact on 
the foetus of prenatal cannabis exposure 
including neurological development, visual 
problem solving, visual-motor coordination 
and visual analysis, decreased attention 
span and behavioural problems. Therefore 
since 2015 ACOG has repeatedly warned 
obstetricians to deliver the message to 
pregnant women not to smoke cannabis or 
be exposed to SHCS (Gynecologists 2015).
CONCLUSION:
In Australia, medicinal cannabis has been 
a legal treatment modality since 2017 for 
several approved medical conditions. 
The current available medicinal cannabis 
products that may be prescribed and 
approved by the TGA include both plant-
based and synthetic products. The route 
of administration may be in the form 
of a vapour (Queensland Health 2017) 
but currently, no vaporisers have been 
approved and registered as medical devices 
in Australia (Commonwealth of Australia 
2017). Therefore, smoking is still the most 
common route of administration of 
medicinal cannabis. In this case, community 
nurses may inhale cannabis substances 
while they are carrying out the duty of 
care in the patients’ home. Exposure to the 
cannabis substances at work may pose some 
serious work health and safety issues. This 
review found that the effects and impact of 
SHCS may include:
• increased risk of cardiovascular 
diseases;
• deleterious effects on the foetus if the 
nurse is pregnant;
• altered cognitive function leading to 
increase the risk of medical errors and 
car accident while commuting between 
visits;
• risk of drug addiction; 
• positive road-side drug tests; and
• loss of nursing registration due to 
misuse of illegal substances.
If a nurse tests positive in a drug test, the 
court may impose penalties for the charge. 
In addition, it is a breach of the professional 
conduct while providing direct patient care 
under the influence of illicit substances. The 
healthcare registration board may require 
them to go through the disciplinary hearing 
process. The nurse may be suspended from 
work or on restricted duty until the hearing 
process is completed. 
The use of medicinal cannabis as a 
treatment modality is new to Australian 
nurses. More research and education are 
required in this area to strengthen policies 
and procedures around the nursing 
practices relating to the care of patients who 
choose to use smoked medicinal cannabis to 
manage their chronic or terminal medical 
conditions. 
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